Company BioInvent International AB

Equities

BINV

SE0015244520

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for BioInvent International AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Stockholm Other stock markets 11:29:34 2024-04-17 am EDT			5-day change	1st Jan Change
21.5 ^SEK	+2.63%		+16.22%	+13.40%

Apr. 03	BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	MT
Feb. 22	Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Number of employees: 111

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	326	100.0 %	71	100.0 %	-78.09%

SEK in Million	2022	Weight	2023	Weight	Delta
United States 66.3 %	273	83.8 %	47	66.3 %	-82.66%
Sweden 25.6 %	26	7.9 %	18	25.6 %	-28.75%
Europe 4.1 %	27	8.3 %	3	4.1 %	-89.11%
Other Countries 4.0 %	-	-	3	4.0 %	-

Managers	Title	Age	Since
Martin Welschof CEO	Chief Executive Officer	63	18-08-31
Stefan Ericsson DFI	Director of Finance/CFO	61	97-12-31
Marie Moores COO	Chief Operating Officer	-	22-01-31
Björn Frendéus CTO	Chief Tech/Sci/R&D Officer	51	00-12-31
Andres McAllister CTO	Chief Tech/Sci/R&D Officer	68	16-12-31
Cecilia Hofvander IRC	Investor Relations Contact	-	21-01-31
Emma Meurling HRO	Human Resources Officer	-	-
Ingunn Munch Lindvig LAW	General Counsel	-	23-06-11
Sylvie Ryckebusch PRN	Corporate Officer/Principal	-	22-06-08
Kristoffer Rudenholm Hansson PRN	Corporate Officer/Principal	50	15-12-31

Members of the board	Title	Age	Since
Bernd Seizinger BRD	Director/Board Member	67	17-12-31
Leonard Kruimer CHM	Chairman	66	16-05-11
Vincent Ossipow BRD	Director/Board Member	55	16-05-11
Thomas O. Hecht BRD	Director/Board Member	73	20-07-02
Erik Esveld BRD	Director/Board Member	-	21-04-28
Nanna Liebach Lüneborg BRD	Director/Board Member	49	22-07-11
Kristoffer Bissessar BRD	Director/Board Member	56	17-12-31
Natalie Berner BRD	Director/Board Member	34	22-07-11
Martin Pålsson BRD	Director/Board Member	45	21-12-31
Elin Birgersson BRD	Director/Board Member	39	22-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,804,362	57,013,147 ( 86.64 %)	0	86.64 %

Name	Equities	%	Valuation
Redmile Group LLC 15.39 %	10,127,860	15.39 %	16 M kr
Van Herk Investments BV 10.08 %	6,630,965	10.08 %	11 M kr
Forbion Capital Partners Management Holding BV 9.422 %	6,200,285	9.422 %	10 M kr
HBM Partners AG 7.803 %	5,135,000	7.803 %	8 M kr
HBM Partners AG (Investment Management) 7.803 %	5,135,000	7.803 %	8 M kr
Omega Fund Management LLC 6.304 %	4,148,211	6.304 %	7 M kr
Swedbank Robur Fonder AB 1.944 %	1,279,505	1.944 %	2 M kr
Dharminder S. Chahal 0.4559 %	300,000	0.4559 %	476 964 kr
Erik Penser Bank AB (Invt Mgmt) 0.3649 %	240,132	0.3649 %	381 781 kr
Tanglin Asset Management AB 0.1087 %	71,547	0.1087 %	113 751 kr

BioInvent International AB

The Gamma Building Ideongatan 1

223 70, Lund

+46 4 62 86 85 50

http://www.bioinvent.com

address BioInvent International AB(BINV)

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.5 SEK

Average target price

83 SEK

Spread / Average Target

+286.05%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOINVENT INTERNATIONAL AB	+13.40%	126M
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.09B
ARGENX SE	-1.02%	22.05B
BIONTECH SE	-18.14%	20.81B
GENMAB A/S	-6.87%	19.06B
WUXI APPTEC CO., LTD.	-40.70%	16.05B
BEIGENE, LTD.	-26.89%	14.01B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.38B
SAREPTA THERAPEUTICS, INC.	+22.25%	11.01B

Bio Therapeutic Drugs